Pregnancy in women with congenital heart disease by van Hagen, Iris M. & Roos-Hesselink, Jolien W.
616
Pregnancy in women with 
congenital heart disease
western Europe is congenital heart disease (CHD) whereas in 
African nations it is rheumatic valvular disease.(2) Due to advances 
in medical care and improvement of surgical facilities, children with 
congenital heart disease now have an excellent survival rate, with 
over 90% of children reaching adult age. Consequently the number 
of women with repaired congenital heart disease contemplating 
pregnancy is increasing. An on-going worldwide registry demon-
strated two-thirds of the structural heart disease in pregnant 
women consists of congenital heart disease.(3)  
There is a lack of data concerning exact cardiovascular maternal 
mortality in South Africa. Overall maternal mortality in 2010 in 
South Africa was 300 women per 100 000 live births versus less 
than 20 per 100 000 in European countries. However, this rate of 
mortality shows a clear decline over the past two decades, probably 
mainly due to a better accessibility of health care systems.(4) 
With better access to health care, an accurate approximation of 
the increasing numbers of women with adult congenital heart 
disease in child-bearing age will become available.
PRE-CONCEPTION COUNSELLING
As pregnancy causes a haemodynamic burden, women known with 
congenital heart disease should be appropriately informed and 
advised, preferably before conception, thus at young age. The aim 
of pre-pregnancy counselling is to empower women to make 
informed choices about their plans to raise a family and to attempt 
to optimise the maternal condition pre-pregnancy with elective 
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Pregnancy is a challenge to the cardiovascular system even in 
healthy women. There are significant changes in circulating volume, 
arterial resistance, heart rate and structural changes in both the 
heart and great vessels.  In structural heart disease, the capacity of 
the heart to adapt may be insufficient to cope, leading to a higher 
risk of complications such as arrhythmias or heart failure. Patients 
with compromised ventricular function, severe valve disease, pul-
monary hypertension or cyanosis are especially at risk. The risk of 
aortic dissection is also elevated during pregnancy due to changes 
in hormonal status in addition to the haemodynamic changes. 
Furthermore there is an increased risk of bleeding and thrombosis. 
Pregnancy may also have an irreversible adverse effect on cardiac 
function in patients with congenital heart disease. Finally, mothers 
diagnosed with a congenital heart defect have an elevated risk of 
having a child with a congenital defect, dependent on the specific 
diagnosis. The influence of pregnancy on heart disease and vice 
versa has consequences for the outcome of mother and child.
Cardiovascular disease is the leading cause of mortality in pregnant 
women in developed countries, whereas in Sub-Saharan countries 
the obstetric complications, such as hemorrhage and sepsis lead 
more often to maternal mortality. Heart disease is, however, the 
main non-obstetric cause of death in developing countries.(1) 
There is a difference in type and severity of cardiac diseases in preg-
nant women in African countries compared with those in West-
European countries. The most important underlying pathology in 
Due to the enormous improvements in the treatment of 
children with congenital heart disease, an increasing number 
of patients reach adulthood nowadays. To achieve the aim of 
excellent care concerning pregnancy in this patient popula-
tion, a pro-active discussion of pregnancy with all women in 
this patient population is essential. Several risk stratifi cation 
models have been developed in order to identify high risk 
pregnancies and better inform patients about these risks. 
Counselling and dedicated care are needed to optimise both 
maternal and fetal outcomes. Better access to health care 
systems contributes to further improvements in mortality 
and morbidity. Furthermore a well-developed, multidiscipli-
nary plan for each individual patient concerning pregnancy, 

















intervention carried out if necessary.  Depending on their under-
lying condition, clear and extensive information should be provided 
and assessment of risks should be carried out. 
When a patient presents contemplating pregnancy, pre-pregnancy 
analysis of the current situation is mandatory. This usually involves a 
detailed overview of the history with diagnosis and past-inter-
ventions, a new echocardiographic examination to measure the 
ventricular function and residual lesions and also an exercise test to 
assess the clinical condition. In some cases an MRI or CT scan is 
required, especially when the aorta may be dilated. After careful 
assessment of the current situation, several issues have to be 
discussed with the future parents: firstly, the risk for the mother to 
developing complications including the possible irreversible effect 
of pregnancy or even not surviving the pregnancy. Secondly, medi-
cation use of the mother has to be discussed, as some medication 
may be harmful for the fetus. Possible alternatives can be discussed. 
Or, for instance in the case of ACE-inhibitor use for diminished 
ventricular function, stopping the medication with new echo and 
exercise testing to assess the clinical condition and ventricular 
function after 3 months may be appropriate. Also the risk of 
miscarriage and fetal problems should be extensively explained to 
the future parents. Finally, the life expectancy of the mother should 
be discussed. 
Risk stratifi cation
It is important to stratify risk by using the tool conducted by the 
World Health Organisation (WHO). It has been shown that 
this risk stratification has the best predictive power of the 
current available risk models (Table 1).  There is a low incidence of 
events in women in WHO I, while patients classified as WHO 
IV (for instance pulmonary arterial hypertension) have a very high 
risk and indeed should be advised against pregnancy. In WHO III 
frequent follow-up should be carried out during pregnancy.(5)  
Apart from the WHO classification, several other risk scores have 
been developed. Table 2(6) shows the additional predictors of 
maternal cardiovascular events. We listed only the unique risk 
TABLE 1: Modified WHO classification of maternal cardiovascular risk: Disease specific.(5)






Successfully repaired simple lesions (i.e. ASD, VSD, PDA)
Mild pulmonary stenosis
Mild mitral valve prolapse
Small patent ductus arteriosus
Unrepaired ASD or VSD
Repaired tetralogy of Fallot
Mild left ventricular dysfunction
Valve disease (not considered WHO I or IV, and non-mechanical)
Marfan, without aortic dilatation





Marfan: Aortic dilatation 40-45mm
Bicuspid aortic valve: Aortic dilatation 45-50mm
Other complex congenital heart disease
Pulmonary arterial hypertension
Severe left (systemic) ventricular dysfunction (LVEF <30%, NYHA III-IV)
Severe mitral or symptomatic aortic stenosis
Marfan: aortic dilatation >45mm
Bicuspid aortic valve: Aortic dilatation >50mm
Severe aortic coarctation
No detectable increased risk 
of maternal mortality and no/
mild increase in morbidity.
Small increased risk of 
maternal mortality or 
moderate increase in 
morbidity.
Signifi cantly increased risk of 
maternal mortality or severe 
morbidity. 
Extremely high risk of 
maternal mortality or severe 
morbidity; pregnancy 
contraindicated. 
WHO = World Health Organization. ASD = Atrial Septal Defect. VSD = Ventricular Septal Defect. PDA = Patent Ductus Arteriosus.
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factors, as some overlap was seen between the studies. The first 
prediction model developed was composed by the CARPREG 
investigators(7) with validation carried out on a prospective cohort 
with mainly congenital heart disease.(8)
Validation of the CARPREG score by Khairy, et al., resulted in some 
additional predictors.(9) However, the CARPREG score might over-
estimate the maternal cardiac risks. Adding more predictive factors, 
conducted by the ZAHARA group approximates a more accurate 
estimation of risk.(10) For more details on the specific prediction 
rules, we would like to refer to the original articles.(7,9-12)
Subfertility 
Some results have been published on subfertility in women with 
congenital heart disease (for instance with a Fontan circulation). 
This might be caused by the hypoxemia before the interventions 
at neonatal and infant age, resulting in diminished function of the 
ovaries.(13,14) In case of suspicion of subfertility, a patient should be 
referred to a specialist with expertise in this field. However, fertility 
treatment should be embarked upon with caution, since ovarian 
hyperstimulation may be life-threatening to women with heart 
disease, and multiple pregnancies poorly tolerated.
Psychological impact
Alongside  the physical topics discussed in this article, one should 
be aware of the psychological burden as well, with the combina-
tion of having a preexistent congenital heart disease and the 
worry of potential complications of a pregnancy. There needs to 
be awareness of the comprehensive effect on mental status. A 
thorough conversation with these women should be part of pre-
conception counselling.
PREGNANCY: OUTCOME OF PATIENTS WITH 
SPECIFIC LESIONS
In a large registry of pregnant women with structural heart disease, 
of which 66% had CHD, maternal mortality was notably higher than 
expected (0.5% in patients with congenital heart disease versus 
0.007% in the normal population). Moreover, 20% of patients with 
CHD are admitted to the hospital during pregnancy, compared to 
2% in the normal population. Overall, in the CHD population, 8% 
needs treatment for symptomatic heart failure during pregnancy, 
while supraventricular arrhythmias were found in 0.7% and 
ventricular arrhythmias in 1.6% of patients.  Frequency of obstetric 
complications is similar in those with congenital heart disease 
compared to the normal population, although caesarean section 
rates were higher. Fetal outcome (Apgar score, preterm births, fetal 
and neonatal death, as well as birth weight) is slightly worse in 
patients with congenital heart disease compared to the normal 
population.(3) 
ASD, VSD and PDA
Septal defects are classified as WHO I, in the case of a small or 
corrected defect, with little additive risks compared to pregnancy in 
healthy women. However, patients with a large shunt are at risk of 
developing heart failure and paradoxical emboli. Patients with a 
very large shunt complicated by the Eisenmenger syndrome will be 
discussed elsewhere in this article.
In women with unrepaired atrial septal defects (ASD) more neo-
natal events occur than in the normal population. Pre-eclampsia, 
small-for-gestational-age and fetal mortality are more frequently 
encountered in this group of patients. Additionally, there is 
contradictory evidence on the need to repair an ASD  before 
pregnancy. It is thought that they have an elevated risk of being 
affected by a paradoxical thrombo-embolic event, especially during 
pregnancy because of the presence of a hypercoagulable state and 
pressure of the fetus on the vena cava inferior causing stasis. The 
latest European guidelines only suggest providing prevention 
through compression stockings and limited supine position and 
immobilisation. A catheter device closure or surgical intervention 
needs to be considered pre-pregnancy if an ASD is of haemo-
PREGNANCY IN CONGENITAL HEART DISEASE
TABLE 2: Predictors of maternal cardiovascular event 
during pregnancy.
Modified from Pieper(6) 
NYHA = New York Heart Association. LVEF = Left Ventricular Ejection Fraction.
BNP = B-type Natriuretic Peptide.
Prediction model Predictor
CARPREG  Prior cardiac event
  NYHA III or IV, cyanosis
  Left heart obstruction
  LVEF <30%
ZAHARA  Cardiac medication
  Atrioventricular valve regurgitation
  Mechanical valve prosthesis
  Cyanotic heart disease
Additional
Khairy   Right/subpulmonary ventricular dysfunction or severe 
pulmonary regurgitation
  Smoking history
Song  Right ventricular dilatation
  Pulmonary arterial hypertension
Tanous  Anticoagulation

















dynamic importance, as the haemodynamic burden of pregnancy 
may worsen the situation with increasing shunt and the risk of 
heart failure.(15)  
A cohort of patients with an isolated ventricular septal defect 
(VSD) reported in literature, showed a higher frequency of pre-
eclampsia, particularly in patients with an unrepaired VSD, while 
patients with a repaired VSD tended to have more premature 
deliveries and neonates who were small-for-gestational-age. How-
ever, maternal cardiovascular events are rarely seen.(16) 
The outcome of women with a patent ductus arteriosus during 
pregnancy is mainly dependent of the presence of pulmonary 
hypertension, this topic is discussed elsewhere in this article. 
Furthermore, apart from several case reports, no specific data have 
been reported on this subject.
Atrioventricular septal defect (AVSD)  
Outcome of pregnancy in women with an atrioventricular septal 
defect (AVSD) is dependent on the presence of left atrioventri-
cular valve regurgitation and presence of ventricular dysfunction. To 
reduce complications it is advisable to consider valve repair prior 
to pregnancy in case of severe regurgitation. Some patients with 
AVSD have complex left ventricular outflow tract obstruction 
secondary to septal attachments of the left atrioventricular valve. 
Such obstruction needs careful assessment, and if necessary, relief, 
before embarking on a pregnancy.
In a report of 62 pregnancies, there was a high occurrence of 
NYHA deterioration during pregnancy (60.4%), of which 22.9% 
was persistent for more than a year after delivery, mainly in patients 
with presence of a residual ASD (with left-to-right shunt). 
Arrhythmias were reported in 19% of patients, in particular those 
with a history of arrhythmias. A relatively high neonatal mortality 
rate of 4.2% was found, directly associated with CHD recurrence 
in the offspring.(5,17) 
Ebstein
Without presence of cyanosis, women with an Ebstein’s anomaly 
undergo pregnancy relatively smoothly. In an article of 1994, 
describing 111 pregnancies, there were no serious maternal 
complications reported, arrhythmias did not occur more often than 
in non-pregnant women. However, neonatal outcome showed 
several adverse results, including prematurity (27%), lower birth 
weight (especially in cyanotic women) and fetal mortality (18%).(5,18) 
A recent small retrospective study, showed that NYHA classification 
and severity of tricuspid regurgitation before onset of pregnancy 
are of predictive value for outcome after gestation.(19) 
Tetralogy of Fallot 
Cardiac complications such as arrhythmias and symptomatic right 
heart failure are reported in 12% of these pregnancies. A cohort 
describing this prevalence, showed no specific predictors for 
adverse events during pregnancy in patients with repaired Tetralogy 
of Fallot. However, there tended to be an association between 
severity of pulmonary regurgitation and symptomatic heart 
failure.(20) 
Evidence on outcome of pregnancy in severe pulmonary regur-
gitation is conflicting, possibly due to small numbers of patients 
actual embarking pregnancy. Current guidelines suggest considering 
pulmonary valve intervention before onset of gestation, specifically 
in patients with dysfunction of the right ventricle.(5) 
Additionally, in the study of Balci, et al. medication use before 
pregnancy, showed a negative association with the child’s out-
come. Arrhythmias were the main cause of maternal events. They 
occurred most often in patients who had a history of arrhythmias 
and patients with a prior pulmonary valve replacement. An asso-
ciation between maternal events and  fetal outcome was found, i.e. 
small-for-gestational-age.(21) 
Transposition of the great arteries (TGA)
Women treated with a Senning or Mustard procedure have an 
increased risk of developing cardiac morbidity during pregnancy, 
such as supraventricular arrhythmias and heart failure. These 
arrhythmias may be associated with the extensive atrial scarring, 
being substrate for electrophysiologic disbalance. Spontaneous 
miscarriages are reported, but data are subject to survival and 
publication bias. Moreover there are obstetric problems: pre-
maturity, in about 30% of cases, as well as hypertensive disorders 
associated with pregnancy.(22) 
Patients present more often with preeclampsia which may be 
associated with a lower perfusion of the placenta. In these patients 
this is possibly caused by a decreased ability of the systemic ventricle 
to meet the demand of pregnancy for an increase of cardiac output. 
High fetal mortality has been reported: 11.7% compared to 1% in 
the normal population.(23) As there is a lack of specific risk factors to 
predict this adverse outcome, frequent follow-up of these patients 
is recommended during gestation. Impaired function of the right 
ventricle, as well as severe valvular dysfunction, is a valid reason to 
dissuade pregnancy.(5) There are little data on women treated with 
the more recent approach: the arterial switch operation,(24) but 
outcomes are expected to be better than for the Senning/Mustard 
approach, since the left ventricle is the systemic ventricle and there 
is no extensive atrial scarring to act as a substrate for arrhythmia.
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Fontan palliation
Small numbers of pregnant women with a Fontan circulation have 
been described in literature. In the small series published so far 
these patients showed a high risk of developing complications 
(multiple supraventricular tachycardias, NYHA deterioration) as 
well as hemorrhagic complications and obstetric problems, for 
instance prematurity, premature rupture of membranes and neo-
natal death.(14) Fontan patients have a less than favorable outcome 
when it comes to completion of pregnancy. Miscarriages and 
abortion rates are higher compared to most of the other congenital 
heart diseases with about 50% of pregnancies completed.(22,25) 
Guidelines advise against pregnancy in “Fontan patients with 
depressed ventricular function, moderate to severe atrioventri-
cular valvular regurgitation, with cyanosis or with protein-losing 
enteropathy”.(5) As these patients are in WHO IV, this is a group 
with highest risk of complications. The outcome in more recently 
operated Fontan patients needs to be awaited and may be more 
positive.
Aortic pathology
Due to an increase in cardiac output and hormonal changes 
affecting the arterial wall, patients with aortic disease have a higher 
risk of dissection during pregnancy. If a patients history reveals an 
earlier dissection or dilatation of the aorta, the (pre-) pregnancy 
counselling and guidance should definitely be carried out in a 
specialised center, with cardiovascular surgery available and should 
include optimal imaging of the entire aorta. 
A large review of Immer, et al., aiming to determine predictive 
factors of aortic dissection, suggests that in all cases, a dilated 
aorta (larger than 40mm) preferably has to be surgically treated 
before onset of pregnancy, to minimise the risk of occurrence of 
dissection.(26) 
Recent European guidelines are more conservative: they suggest 
consideration of surgery pre-pregnancy in patients (except for 
Marfan, as will be discussed) with an aortic dilatation of larger 
than 50mm. Also, when a patient presents with a dilated aorta 
during pregnancy,  surgery must be considered if the diameter 
appears to be larger than 50mm or is rapidly progressive.(5) In case 
of an acute dissection type A, advised policy depends on duration 
of gestation. Under 30 weeks, acute surgery should be done. In 
case of a pregnancy duration over 30 weeks, an emergency aortic 
replacement should be preceded by caesarean section. 
Bicuspid aortic valve 
Fifty per cent of these patients have a dilated ascending aorta, 
which should be evaluated preferably before pregnancy to assess 
the diameter. Surgery may be required if the aortic diameter 
exceeds 50mm. 
A bicuspid valve is a common underlying mechanism for both aortic 
stenosis and regurgitation. In asymptomatic  severe aortic valve 
stenosis (valve are ≤1.0cm2) with normal ventricular systolic func-
tion and a normal exercise test (ie normal capacity, normal blood 
pressure rise and no ECG changes), appropriate permissive advice 
can be given: pregnancy is likely to be tolerated with careful 
specialist monitoring. If the patient  is symptomatic or has an ab-
normal exercise capacity, guidelines suggest pregnancy should be 
discouraged until the stenosis is treated.(5) 
The same approach is advised in the case of severe aortic 
regurgitation, although pregnancy generally is better tolerated as 
systemic vascular resistance lowers, with a favourable effect on 
regurgitation. Guidelines on valvular disease suggest consideration 
of pre-pregnancy surgery, if a patient is symptomatic or has a 
diminished systolic ventricular function.(27) 
Coarctation of the aorta
In coarctation, counselling prior to pregnancy is also important as 
the patient may need (first or re-) intervention pre-conceptionally. 
However, whether or not these patients have had an intervention, 
the risk of aortic rupture or cerebral aneurysm is not zero, especially 
in those with hypertension. Pregnancy related hypertensive dis-
orders are more frequent in this population. Adequate follow-up of 
blood pressure is essential. Lowering the blood pressure has to be 
considered, but with extra caution in pregnant patient, because 
antihypertensive medication can lower the placental perfusion.(5,22) 
Marfan Syndrome
Certain risk factors for dissection during pregnancy in patients with 
Marfan have been revealed in a large review. An aortic root dia-
meter of more than 40mm and a significant increase in this dia-
meter appeared to be risk factors of dissection.(26) If there is a family 
history of dissection in a patient with Marfan, the risk on dissec-
tion is higher. Even in patients who had already undergone an 
aortic root replacement, there’s still an elevated risk of dissec-
tion as the whole aorta is involved in the disease process. When 
the aortic root diameter exceeds 45mm it is advised to perform 
surgical treatment pre-pregnancy.(5)
Recent prospective research conducted in a population of only 
women with Marfan (aortic root diameter before pregnancy 
25-45mm, mean 37 ± 5mm) showed no increased dilatation, 
dissection or rupture of the aorta. However, there seems to be a 
slightly accelerated growth of diameter in pregnant women with an 
aortic root of ≥40mm. The discrepancy of results might be caused 
by the large range in diameter included in this cohort.(28)

















Pulmonary valve stenosis or regurgitation
Severe pulmonary valve dysfunction (stenosis or regurgitation) can 
lead to maternal complications such as arrhythmias and heart 
failure. In addition to the maternal complications there is a variety 
of general and neonatal complications reported. In pulmonary 
stenosis, hypertension related disorders were reported in 15% of 
women, prematurity in 17% and offspring mortality is seen in 4.8% 
in a cohort of 81 pregnancies. In this study there were three 
patients, with a corrected stenosis, presenting with a thrombo-
embolic event in the absence of risk factors besides the pregnancy. 
This finding was not seen in other studies and needs further 
investigation, before drawing firm conclusions.(5,29) Percutaneous 
pulmonary valvuloplasty can be safely performed in pregnant 
women with severe pulmonary stenosis and suitable valve mor-
phology.
In case of pulmonary valve regurgitation (with or without associated 
other defects and whether or not it is combined with an RV outflow 
obstruction) there has to be awareness of the predictive value of a 
severe regurgitation with respect to the risk of symptomatic right 
heart failure.(30) 
Pulmonary hypertension, Eisenmenger and cyanosis 
A different approach to the patient is needed in all of the above 
described congenital heart diseases, if pulmonary hypertension 
(PH), Eisenmenger or cyanosis is present. Risks for adverse 
outcomes in mother and child are significantly higher and will be 
explained in this section.
Pulmonary hypertension
There is a distinct difference in maternal mortality if the disease is 
associated with PH, with a mortality rate varying from 17-33%.(5) 
Most patients die peri- or postnatal, with several possible etiologies. 
It may be due to blood loss and subsequently a volume shift 
affecting a hypovolemic right ventricle that is prone to failure. It can 
either be due to pulmonary thrombosis, as pregnancy causes a 
hypercoagulable status and delivery provokes stasis due to fetal 
pressure on the vena cava inferior, while PH frequently goes 
together with pulmonary vascular changes. A combination of these 
factors contributes to an environment more prone to pulmonary 
thrombosis. Lastly, the pulmonary vascular resistance increasing 
during pregnancy in PH patients, and elevating even more during 
delivery, can also lead to maternal death. Neonatal mortality in this 
group can be as high as 10-13%.
A clear cutoff value does not exist; even modestly elevated pul-
monary artery pressures confer a high risk of maternal death. If 
a woman with pulmonary hypertension nevertheless wants to 
proceed with pregnancy, frequent follow-up is advised in a special-
ised pulmonary hypertension centre, at least monthly. Also, mode 
and timing of delivery should be discussed and prepared in a multi-
disciplinary nature beforehand. 
Recently a small study reported the pregnancy of 10 patients with 
pulmonary hypertension. These patients were administered on 
selected targeted drugs and continued taking these drugs during 
pregnancy. They tolerated pregnancy relatively well. Teratogenic 
effects (of some targeted drugs like Bosentan) have to be evaluated 
and discussed before continuation during pregnancy.
With these recent relatively positive results, further research should 
be awaited.(5,31) 
Eisenmenger
In Eisenmenger patients the risk for maternal mortality is as high as 
20-50% and also fetal outcome is hampered, especially if oxygen 
saturation is below 85%, with the chance on a live birth being only 
12%. A patient should be advised against pregnancy and dis-
continuation of an ongoing gestation should be offered. However, 
termination of pregnancy is not without risks either, as anaesthesia 
is required.(5,22) 
Cyanosis
In women with a persistent right-to-left shunt, surviving to 
reproductive age without significant pulmonary hypertension, risks 
during pregnancy are dependent on the oxygen saturation. In a 
cohort of 44 women (96 pregnancies) it was demonstrated that 
if the oxygen saturation was 90 % or more, then there was a 
92% chance that the pregnancy would be successful. Also they 
can tolerate pregnancy relatively well, although in the overall 
group there were a lot of heart failure presentations. But neo-
natal outcome is definitely impaired if oxygen saturation is lower 
than 85%: in 17 pregnancies only 2 neonates survived.(32) So baseline 
oxygenation before pregnancy is an important factor to take into 
account in women with cyanotic congenital heart disease. Guidelines 
advise performing an exercise test to objectively assess possible 
decrease in saturation during exercise.(5)
MEDICATION
The use of medication should always be discussed with future 
parents. Some medication is potentially toxic to the fetus. Therefore, 
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careful consideration has to be made as medication cannot always 
be simply withdrawn. The woman may have to accept a balance 
of risk between the risk to the mother (and therefore the fetus) 
of stopping a drug, versus the risk to the fetus of continuing it. 
Angiotensin-converting enzyme inhibitors and angiotensin recep-
tor blockers should be stopped before the onset of pregnancy 
because fetal adverse effects have been described, for example 
oligohydramnion, growth restriction, renal failure due to renal or 
tubular dysplasia, hypocalvaria (cranial hypoplasia), cardiac defects 
and even intrauterine fetal death.
Beta-blockers possibly have an effect on the birth weight of 
the child, although there is uncertainty as to whether this effect 
could be related to the underlying condition rather than the drug 
itself. A recent analysis of a large registry found differences in birth 
weight between the several indications for the use of beta block-
ade. For instance, a clear effect was found in patients with valvular 
heart disease or arrhythmias, while no effect was found in patients 
treated with beta-blockade because of hypertension.(33) Also the 
type of beta blocker may be important; atenolol in particular is 
considered likely to reduce intrauterine growth.(5)  
Amiodarone has an effect on the thyroid gland of the fetus. Women 
on this drug should be withdrawn if possible before pregnancy, 
however refractory ventricular arrhythmias can be an exception 
for this.(34) The long half life of amiodarone means that stopping 
it during a pregnancy may not benefit the fetus – it is still exposed 
to the drug.
Advice for the use of Vitamin K antagonists differ depending on the 
trimester. The fetus is at risk of teratogenicity during the 1st 
trimester, and of intracerebral bleeding throughout the pregnancy 
and delivery. Clear, concise advise is hard to give, but the European 
Society of Cardiology(5) has gone to great efforts to provide guide-
lines, especially concerning patients with mechanical valves. When a 
patient is taking a Vitamin K antagonist in week 6-9, the risk of 
developing embryopathy is about 6% and is probably related to the 
dose. The decision on anticoagulation should be made together 
with the patient after explaining the options to the patient and her 
partner. The options include continuing the oral anticoagulation if 
the patient uses a relatively low dosage (<5mg warfarin, <3mg 
phenprocoumon, <2mg acenocoumarol) or switching to (low 
molecular weight) heparin from the 6th week until the 12th week 
of gestation if there is a need for a relatively high dosage (>5mg, 
>3mg, > 2mg respectively). If there has been a choice to discon-
tinue the vitamin K antagonist, anticoagulation can be switched 
to either low molecular weight heparin (with an anti-Xa check 
weekly) or unfractionated heparin (at least twice daily check of 
aPTT). The decision also depends on the indication for anti-
coagulation (for instance type and position of a mechanical valve). 
In the second trimester a patient can be restarted on oral 
anticoagulation. In the third trimester it’s advisable to again switch 
to LMWH or UFH at 36 weeks. Thirty-six hours before delivery 
LMWH should then be switched to UFH, as it can be stopped 
several (4-6) hours before the delivery, and restarted 4-6 hours 
after (if there is no significant hemorrhage).(5) 
MODE OF DELIVERY 
Mode of delivery should be discussed early in pregnancy preferably 
with a specialised team consisting of cardiologists, obstetricians and 
anesthesiologists with expertise in this field. Vaginal delivery is 
considered the mode of choice in most patients with congenital 
heart disease. Exceptions should be made for women with aortic 
disease involving an aortic root diameter of more than 45 mm or 
dissection in the past, women who were administered on oral 
anticoagulation during onset of labour or women in acute heart 
failure or acute aorta dissection.(5) 
Caesarean section (CS) is associated with more obstetric com-
plications such as thromboembolic events, infection and hemor-
rhage.(35) In a recent prospective cohort of 1 262 women with 
structural cardiac disease (67% congenital heart disease) vaginal 
delivery appears at least as good as CS (with no clear difference 
in outcome between planned and emergency CS). Moreover, 
caesarean section is also associated with a higher occurrence of 
prematurity and a lower birth weight.(36) 
Guidelines prefer vaginal delivery for most patients, with epidural 
anaesthesia for continuous pain management, to limit the haemo-
dynamic changes in the actual delivery.(5)
Infective endocarditis is rarely seen during pregnancy in congenital 
heart disease. With a lack of evidence on association between 
endocarditis and pregnancy or delivery, the guidelines advise no 
additional endocarditis prophylaxes during vaginal delivery or 
caesarean section. Selected patients with a prosthetic valve or 
prosthetic material for valve repair, patients who have had previous 
endocarditis and patients with cyanotic congenital heart disease 
without surgical repair, with residual defects or palliative shunts or 
conduits are at high risk. If congenital heart disease is repaired with 
prosthetic material, it is advisable to prescribe prophylaxis for up to 
6 months after the intervention.(37)


















Rate of recurrence is a disease-specific topic. In Table 3, recurrence 
rates are listed.(17,18,20,38-43)
FEATURE RESEARCH
The majority of current evidence on pregnancy in adult congenital 
heart disease consists of relatively small cohorts and case series. 
Subsequently, publication and selection bias have to be taken into 
account. Large prospectively studies are needed for future research 
to increase our knowledge on this important topic. The Registry on 
Pregnancy and Structural Heart Disease (ROPAC) was initiated to 
observe a large number of women during pregnancy, with pre-
liminary structural heart disease, including congenital disorders, but 
also patients with valvular heart disease, cardiomyopathy, ischaemic 
heart disease, aortic disease or pulmonary hypertension can be 
included. By collecting data in this registry, we can provide a solid 
foundation for further risk stratification and may form the basis 
for randomised controlled trials.(44) Information about this registry 
can be found at: http://www.escardio.org/guidelines-surveys/eorp/
surveys/pregnancy.
CONCLUSION
In most women with congenital heart disease, pregnancy is well 
tolerated, although there should be awareness of cardiac, obstetric 
and neonatal risk. If a patient presents with the wish to become 
pregnant, she should be referred to a specialised center and the 
parents should get extensive information on these risks. Using 
WHO classification, one can identify women at high risk. The most 
frequent cardiac complications are heart failure and arrhythmias. 
When cardiac events occur, there is a higher risk of complications 
for the offspring as well. Continuing to carry out research in this 
field is important for providing these women the best evidence 
based clinical practice.
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TABLE 3: Recurrence risk of congenital heart disease in offspring: 
Affected mother.(17,18,20,22,38-43)
ASD = Atrial Septal Defect. VSD = Ventricular Septal Defect. PDA = Patent Ductus 
Arteriosus. AVSD = Atrioventricular Septal Defect. TGA = Transposition of Great Arteries. 
*    Range varies to 50% if associated with for instance 22q11.2 deletion.
**  Total recurrence risk, affected mother or father.
***Approximate risk, based on:
   -  recurrence risk of CHD in aortic stenosis is approximately 4.1-5% (regardless of bicuspid 
or tricuspid); 
   - Bicuspid valves: 4.6%, 9.1 and 9.3% recurs in first degree family overall.





Ebstein 3.9 - 6%
Tetralogy of Fallot 2.5-10%*
TGA 0.5%**
Bicuspid aortic valve 4.1-9.3%***
Aortic coarctation 4%
Marfan 50%
Pulmonary valve stenosis 7%
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